WO1998010102A2 - Bacteries multiresistantes, procedes d'obtention et utilisation - Google Patents

Bacteries multiresistantes, procedes d'obtention et utilisation Download PDF

Info

Publication number
WO1998010102A2
WO1998010102A2 PCT/FR1997/001566 FR9701566W WO9810102A2 WO 1998010102 A2 WO1998010102 A2 WO 1998010102A2 FR 9701566 W FR9701566 W FR 9701566W WO 9810102 A2 WO9810102 A2 WO 9810102A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
seq
type
gene
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1997/001566
Other languages
English (en)
French (fr)
Other versions
WO1998010102A3 (fr
Inventor
Patrick Ludovic-Henri Duwat
Alexandra Dorothy Gruss
Emmanuelle Ghislaine Jeanne Maguin
Fabien Claude Rallu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9610926A external-priority patent/FR2753201B1/fr
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Priority to EP97938986A priority Critical patent/EP0941308A2/de
Priority to AU41228/97A priority patent/AU4122897A/en
Priority to CA002266190A priority patent/CA2266190A1/fr
Publication of WO1998010102A2 publication Critical patent/WO1998010102A2/fr
Publication of WO1998010102A3 publication Critical patent/WO1998010102A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46Streptococcus ; Enterococcus; Lactococcus

Definitions

  • the present invention relates to new strains of lactic acid bacteria having resistance to stress, the process for obtaining said strains as well as their use in particular in fermentation processes.
  • the subject of the present invention is new bacterial strains which exhibit increased resistance to stress.
  • bacterial growth in laboratories has been studied for decades and it is known that the growth of bacteria in the laboratory. follows a sigoid curve, thus, when inoculating a fresh medium, there is a latency period during which the bacteria prepares for growth, followed by cell multiplication in which the cells grow exponentially up to 'that the environment becomes a limiting condition for growth. It is at this point that the cells enter what is called the stationary phase during which multiplication is stopped and the metabolism of the cells decreases. Survival during these three growth phases, i.e. the latency, exponential and stationary phases. can vary very significantly depending on the specific growth conditions and the type of strain used.
  • laboratory conditions are optimal conditions for growth, in industrial fermentation processes one can find conditions that lead to the death of bacteria. Below are given examples in which the survival of lactic acid bacteria depends on the growth conditions.
  • L. lactis like other lactic acid bacteria, acidify the medium during their growth and are able to withstand acidic conditions up to pH 4, which is reached during the stationary phase. However, if the culture medium is brutally acidified during the exponential phase, the cells die quickly.
  • the cells can be adapted to low pH by first exposing them to intermediate pH, between pH 5 and 6 for example, before moving to lower pH. In this case, better survival is obtained.
  • L. lactis cells die if they are exposed to high temperatures (eg 55 ° C). However, if they are exposed to intermediate temperatures (37 ° C) before a thermal shock, there is a better survival of the cells.
  • the heat shock genes include in particular dnaJ, grpE-dnaK, groELS and h ⁇ B
  • the genes to involve in repairing damage caused by oxygen include in particular recA and sodA
  • each bacterial species has a specific niche and must therefore be adapted to its particular environment Under these conditions, the regulators of the stress response genes may be different for different organizations
  • control There is a great deal of information concerning the control of stress responses in different bacteria Essentially two types of control seem to exist * one type of control which induces genes in response only to specific stress, the other type of control resulting in the expression of many genes that will protect the cell against different types of stress In bacteria, the first type of control can be done via activators, repressors or metabolites, while the second type of control can be carried out by transcription enzymes, RNA polymerase (by ⁇ factors)
  • the present invention relates to the discovery of genes involved in stress resistance and whose mutation leads to an increase in stress resistance of the corresponding bacteria
  • the present invention relates to bacteria having an improved resistance to stress compared to the parental strain, characterized in that they comprise at least one mutation in a gene which alters the normal activity of said gene, this gene being involved.
  • GTP GTP, (p) ppGpp which we will call GP in the rest of the text, the genes of the clone RI 1 (pstS), RI 4 (arll), RI 5 (glnP), RI 7 (carB), RI 8 ( glnP), RI 14 (arl2), RI 16 (glnP), RI 17 (glnQ), RI 20 (arl3), R2 6 (pstB), R2 9 (reciV), R2 1 1 (arl4), R2 15 (arl5 ), R2 17 (arlT), R2 20 (arl8,
  • the mutation in question may also be a mutation by insertion of a DNA sequence, deletion of a DNA sequence and / or point mutation by means for example of a mutagenic agent or by spontaneous mutation
  • insertion of a DNA sequence use will be made of the introduction of mobile genetic elements such as insertion sequences as will be described in the example with ISS /
  • the DNA when the DNA is inserted, it will be DNA coming from the same species, this so as to keep the acceptability on the agri-food level of the strain thus obtained
  • lactic acid bacteria in particular Lactobacilhts, Lactococcus and Streptococcus
  • the bacteria thus obtained exhibit an increase in resistance to certain stresses or to a set of stress conditions. It is possible to envisage multiple mutations on different genes For each specific problem posed, it is preferable to compose a set of bacteria mutated in different genes and to select the most appropriate mutants for the stress conditions which are likely to arise during the fermentation process.
  • the present invention also relates to a fermentation process using a bacterium according to the present invention and in particular the fermentation processes using milk or milk by-products as the fermentation medium.
  • a fermentation process using a bacterium according to the present invention and in particular the fermentation processes using milk or milk by-products as the fermentation medium.
  • fermented milk products such as yogurts and equivalent products as well as the preparation of cheeses.
  • the bacteria according to the present invention can also be used for the preservation of food products or for probiotic purposes.
  • Figure 1 illustrates the mutagenesis system via the plasmid pGh: ISS /.
  • Figure 2 illustrates the obtaining of mutants lacking foreign DNA.
  • Figure 3 illustrates the identification process of the mute gene
  • Figure 4 represents the biosynthetic pathway of GP SEQ ID N ° 1 to 34 represent the sequences of the mutated genes, at the origin of multiresistance, at the junctions of the insertion plasmid, the microorganisms concerned being from what has been called Selection 1 in the example
  • SEQ ID N ° 35 to 44 represent the sequences of the mutated genes, at the origin of multiresistance, at the junctions of plasmid insertion, the microorganisms concerned being from what has been called Selection 2 in the example
  • SEQ ID N ° 45 to 52 represent the sequences of mutated genes by site-directed mutagenesis
  • SEQ ID N ° 53 to 71 represent a list of the sequences of the mutated genes, in the presence of an acid resistance superior to the parental strain (data not shown) at the junctions of the plasmid insertion, the mutants being derived from the
  • FIG. 1A represents a microorganism cell with its chromosome, into which the plasmid pGh ISS / which contains the replicon pG + host (Ts on), an antibiotic resistance gene (Ab * ⁇ ) and a mobile element ISS / At 30 ° C, the plasmid replicates in the microorganism cell
  • FIG. 1B represents the population of mutant bacterial cells resulting from the integration of the plasmid into the bacterial chromosome after duplication of the ISS / Indeed, at 37 ° C., the plasmid repation is inactive and the plasmid is lost unless the bacteria undergoes transposition event
  • FIG. 2 A represents the chromosomal structure of a mutant obtained by transposition of the ISS / The duplicated ISS elements /, frame the plasmid pG + host At 30 ° C., the rephcation of the pG + host is activated and stimulates the recombination homologous between ISS / duplicate sequences
  • Figure 2B shows the homologous recombination taking place between the two ISS sequences / leading to the excision of the plasmid pGh ISS / which is then lost when the strain is spread at a non-permissive temperature of 37 ° C.
  • the mutated strain contains only one copy of ITSS / which is a sequence originating from the mutated microorganism, which therefore contains no trace of foreign DNA
  • FIG. 3 represents the cloning of the junctions between the ISS / and the chromosome
  • the Hindlll and EcoR ⁇ restriction sites are unique in the transposed structure and are located on either side of the plasmid pG + host
  • Digestion by Hindlll of the Chromosomal DNA of the mutant produces a fragment consisting of the pG + host and the right junction ISS / - chromosome After circularization, this fragment is established as a plasmid in E. coli or other bacteria.
  • the junction is then sequenced by means of primers corresponding to the sequence of the ISS / or that of the pG + host.
  • the left junction ISS / - chromosome is obtained by applying the same procedure after digestion with
  • SEQ ID Nos. 1 to 34 represent the sequences of the mutated genes as they could be determined in accordance with the protocol illustrated in FIG. 3 An "R" code was given to identify each gene concerned Each sequenced junction was compared, in terms of homology, to the sequences of already known microorganisms, and when one of them was identified, it was mentioned NS means that no significant homology with an already known gene could be established The data numeric appearing (for each junction identified), corresponds to the probability that the sequence represented will not be identical to the already known genes mentioned
  • SEQ ID N ° 35 to 44 represent the sequences of the mutated genes as determined in accordance with the protocol illustrated in Figure 3 (unless otherwise indicated)
  • SEQ ID N ° 45 to 52 represent the sequences of internal fragment of certain genes whose junction sequence had already been determined in accordance with SEQ ID N ° 1 to 34.
  • the internal fragment of the gene in question was amplified by PCR then sequenced on the two strands. These fragments were then used to inactivate, by homologous recombination, the corresponding genes in the wild strain so as to verify that the multidrug resistance phenotypes were indeed due to the inactivation of these genes.
  • SEQ ID Nos. 53 to 71 represent only the sequences of the genes whose inactivation has made it possible to demonstrate at least one resistance to the acid of the strains concerned.
  • Lactococcus lactis is a bacterium which, in the wild state, has the following characteristics: on a medium at 30 ° C., whether the pH is 7 or 5.5, it has the same spreading efficiency; on a medium at 37 ° C, the spreading efficiency on pH 7 is 10 ⁇ times higher than that obtained on pH 5.5 or pH 5.
  • a group of mutants comes from the wild strain MG1363 of .Lactococcus lactis and consists of mutants having at 37 ° C a spreading efficiency on a medium at 37 ° C at pH 5.5 between 1 and 0.01 relative to pH 7. Thirty mutants were thus isolated.
  • a second group of mutants comes from the wild strain MG1363 of Lactococcus lactis previously mutated in the recA gene making it sensitive to ultraviolet radiation.
  • This strain called VEL1 122, is sensitive to temperature. It was found that at the temperature of 39.3 ° C. (with a pH of the medium of approximately 7 but not determining) the strain recA had a spreading efficiency of less than 10 " - ⁇ when the wild strain MG1363 had a spreading efficiency of 1. Mutants were selected from the VEL1 122 strain capable of growing at a temperature of 39.3 ° C. About twenty mutants were thus isolated.
  • thermosensitive plasmid pGh ISS / (cf. reference 16).
  • This plasmid consists of the replicon pG + host (Ts ori), a gene for resistance to an antibiotic (in the present case erythromycin) and the mobile element ISS / (cf. FIG. 1).
  • This plasmid has the particularity of replicating in cells at 30 ° C, but not at 37 ° C or more.
  • This plasmid can integrate into the chromosome of bacteria via an ISS / transposition event. During transposition, the entire plasmid, flanked on either side by 1TSS / is integrated into the chromosome.
  • the transposon integration sites are random.
  • the bacteria that have integrated the plasmid pGh: ISS / into their chromosome therefore retain resistance to erythromycin at 37 ° C or more. Consequently, among the bacteria having undergone the above mutagenesis, those which are still capable of growing in the presence of antibiotics on a medium at 37 ° C. or higher are selected. These bacteria have undergone a transposition event which generates random mutations.
  • mutants more resistant to stress were selected according to the methods previously indicated (Selection 1 or 2).
  • the mutants resulting from Selections 1 and 2 are subjected to a temperature of 30 ° C. which activates the rephcation of the pG + host and stimulates the homologous recombination between the ISS / duplicated sequences which results in the excision of the plasmid pGh: ISS /.
  • the bacteria in question therefore contain, inserted in their chromosome, only one copy of the ISS / (cf. Figure 2)
  • the final strain mutated by insertion of the ISS / is stable and does not contain DNA foreign to Lactococcus, it therefore constitutes a food-grade mutant.
  • Lactococcus lactis bacteria thus obtained (Selection 1 or Selection 2 mutants) are then subjected to different stress conditions in respect of which their resistance has been tested compared to that of the parental strain subjected to the same conditions.
  • the genes identified in Table I correspond to SEQ ID Nos. 1 to 34.
  • microorganisms grown at 30 ° C, are directly subjected to a thermal stress of 55 ° C.
  • microorganisms, cultured at 30 ° C are subjected for 15 minutes to a temperature of 37 ° C and then to a thermal stress of 55 ° C. actual survival of the parental strain; this value is then reduced to 1.
  • NAME / KEY RI. 1-EcoRI junction: clone SS80 L. lactis (3e-14)
  • NAME / KEY RI. 1-Hindlll junction: clone SS80 L. lactis (3e-47)
  • NAME / KEY RI. 5-EcoRI junction: GlnQ. E. coli (3. e-1!
  • NAME / KEY RI. 5-Hindlll junction: GlnQ. E. coli (6.6e-3)
  • NAME / KEY RI. 7-Hindlll junction: carbamoyl-phosphate synthase.B.caldolyticus (3.9e-ll)
  • NAME / KEY RI. 8-EcoRI junction: GlnH. E. coli (5.3e-29)
  • CGTNCAATTC CGCTTTTAGT GTTAANAATC TTTATCTTCT ANGGGATTCC TAANCTTCTA 420
  • CAAATCATT 429 (2) INFORMATION FOR SEQ ID NO: 10:
  • CTCGTTTAAC TTATCGTGGC ATAATCTTAT ATCAAGCTAT CTAATCATGT TTTATCACTG 120
  • AACACGTTGT TTGTGTCCTC CAGAAAGCAT TCTGGCATCG CGTCTTTTTT GTCTGCCAAG 300
  • TTTACTTCAC CAGAAGATTT TGTTCCTCCG TGATAGCTTG ATACGGTCAT AAAATCAGTT 300
  • NAME / KEY R2.2-EcoRI junction: Rel. S. equisimilis (1.4e-53)
  • NNATCTCAAC TCGGTCCCCT GTTTTTAATT GAACAGATAA AGGTTTCATA CGTCCATTIA 120
  • GAGCGGCCGC CACCGCGGTG GGATCCTCTA GAGTCTAGGG ACCTCTTTAG CTCCTTGGAA 540
  • AAAATAGTAA AAAGAAAGTC CATGAATTGA TAGCGTGTTT TC ⁇ CCTCCCA AATGATGGTA 540
  • GGTTTTTNNN NNNNNNTGAC TTTATTTAGC TTAAGAGCCG AATGNTATAA ACCTTGTATT 60
  • NAME / KEY R2.3-Hindi junction 11: GuaA. B. subtilis (2.4e-33)
  • TATTACGANC AAACCACCAG CAACTGTTGA GTGGCANTAC CAATAAAAAA ACTGATAGCA 360
  • NAME / KEY R2.6-EcoRI junction: Hypothetical ABC transporter.
  • GACTATTCAA GCCTGAATAA TATTCGGACG ACAATGACCG AATTGGATAG AATGGCAATT 180
  • AACATCTCCT AAAGAATATC ATAATATTAG GGAAAAGAGT AAAAATGAAA GCGCTATAGT 240
  • AAAGCAACTT CCTAAAGACT TGTCAAAAAG AATCCTAAAC CTAGTGTACG CCAAAGTCCT 480
  • TCAACTCNTA TCATTCCTTT AAGGNGCCCC CATTGACAAT ATACCTTGTA TTTGATTTCN 60
  • TAAACTTTGC AACAGAACCC TTGNAAAGTC ATTTTTGGCA GATAAGCGGT CATGGTGTGC 120
  • AAGATTGAGC AAAATGAAAG GATATTTATC CCATTCAACG CCAAAGAGGC CAGTCACATT 240
  • GACAAACATC CAGACTACTA ⁇ ATACCGAGA TAGGTGATAA TAAAAGCCCA CGAACCGACG 300
  • CAACTTTTTC ACGAATATCT TTGATTTGCA TATCAATGAA GTTTTCCATT GACCAGTTCC 300
  • CTCGAGGTCG ACGGTATCGA TAAGCTTGAT ATCGAATTCC TGCAGCCCTG AATTAGTCGA 60
  • NAME / CLE relA gene (inactive in mutant R2.2) strand 2 sequence (complementary)
  • NAME / CLE guaA gene (inactive in mutants R2.3 and R2.14) strand 1 sequence
  • NAME / CLE guaA gene (inactive in mutants R2.3 and R2.14) strand 2 sequence (complementary)
  • AAATTAAAAA ACGATTATTA ATCGTTTTTTTT TATCTTATAA TGAATTAAAT AATTCTTGAA 240
  • CTGTTCAAAA AATTTTTGAA AAAAGCCCTA ANATAAATTC ATCAATCTCC AAGTTCAAAA 660
  • GGTTTTTNNN NNNNNNTGAC TTTATTTAGC TTAAGAGCCG AATGNTATAA ACCTTGTATT 60

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/FR1997/001566 1996-09-06 1997-09-05 Bacteries multiresistantes, procedes d'obtention et utilisation Ceased WO1998010102A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97938986A EP0941308A2 (de) 1996-09-06 1997-09-05 Multiresistente bakterien, verfahren zur herstellung und verwendung
AU41228/97A AU4122897A (en) 1996-09-06 1997-09-05 Multi-resistant bacteria, methods for obtaining them and their uses
CA002266190A CA2266190A1 (fr) 1996-09-06 1997-09-05 Bacteries multiresistantes, procedes d'obtention et utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9610926A FR2753201B1 (fr) 1996-09-06 1996-09-06 Bacteries multiresistantes, procedes d'obtention et utilisation
FR96/10926 1996-09-06
FR9611555A FR2753202A1 (fr) 1996-09-06 1996-09-23 Bacteries multiresistantes, procedes d'obtention et utilisation
FR96/11555 1996-09-23

Publications (2)

Publication Number Publication Date
WO1998010102A2 true WO1998010102A2 (fr) 1998-03-12
WO1998010102A3 WO1998010102A3 (fr) 1998-05-14

Family

ID=26232947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/001566 Ceased WO1998010102A2 (fr) 1996-09-06 1997-09-05 Bacteries multiresistantes, procedes d'obtention et utilisation

Country Status (5)

Country Link
EP (1) EP0941308A2 (de)
AU (1) AU4122897A (de)
CA (1) CA2266190A1 (de)
FR (1) FR2753202A1 (de)
WO (1) WO1998010102A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248541B1 (en) 2000-04-21 2001-06-19 Genencor International, Inc. Screening under nutrient limited conditions
US6534292B1 (en) 2000-05-08 2003-03-18 Genencor International, Inc. Methods for forming recombined nucleic acids
US6582914B1 (en) 2000-10-26 2003-06-24 Genencor International, Inc. Method for generating a library of oligonucleotides comprising a controlled distribution of mutations
WO2006113475A3 (en) * 2005-04-15 2007-03-29 Univ North Carolina State Methods and compositions to modulate adhesion and stress tolerance in bacteria
CN109628364A (zh) * 2019-01-03 2019-04-16 江南大学 一种提高乳酸菌对酸性条件的耐受能力的方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US ZHAO G ET AL: "An Escherichia coli K-12 tktA tktB mutant deficient in transketolase activity requires pyridoxine (vitamin B-6) as well as the aromatic amino acids and vitamins for growth." XP002051188 & JOURNAL OF BACTERIOLOGY 176 (19). 1994. 6134-6138. ISSN: 0021-9193, *
H. HALL ET AL: "Molecular responses of microbes to environmental pH stress" ADVANCES IN MICROBIAL PHYSIOLOGY, vol. 37, 1995, pages 229-272, XP000674366 *
HARTKE A ET AL: "UV-inducible proteins and UV-induced cross-protection against acid, ethanol, H-2O-2 or heat treatment in Lactococcus lactis subsp. lactis." ARCHIVES OF MICROBIOLOGY 163 (5). 1995. 329-336. ISSN: 0302-8933, XP000672629 *
J. FOSTER AND H. HALL: "Inducible pH homeostasis and acid tolerance response of Salmonella typhimurium" JOURNAL OF BACTERIOLOGY, vol. 173, no. 16, août 1991, pages 5129-5135, XP000674345 *
MAGUIN E ET AL: "Efficient insertional mutagenesis in lactococci and other gram-positive bacteria." JOURNAL OF BACTERIOLOGY 178 (3). 1996. 931-935. ISSN: 0021-9193, XP000673892 *
NILSSON D ET AL: "ISOLATION OF PURINE AUXOTROPHIC MUTANTS OF LACTOCOCCUS -LACTIS AND CHARACTERIZATION OF THE GENE HPT ENCODING HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE." MOL GEN GENET 235 (2-3). 1992. 359-364. CODEN: MGGEAE ISSN: 0026-8925, XP002032525 *
RALLU F ET AL: "Lactococcus lactis and stress." ANTONIE VAN LEEUWENHOEK 70 (2-4). 1996. 243-251. ISSN: 0003-6072, octobre 1996, XP000673964 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248541B1 (en) 2000-04-21 2001-06-19 Genencor International, Inc. Screening under nutrient limited conditions
US6534292B1 (en) 2000-05-08 2003-03-18 Genencor International, Inc. Methods for forming recombined nucleic acids
US7037726B2 (en) 2000-05-08 2006-05-02 Genencor International, Inc. Methods for forming recombined nucleic acids
US6582914B1 (en) 2000-10-26 2003-06-24 Genencor International, Inc. Method for generating a library of oligonucleotides comprising a controlled distribution of mutations
WO2006113475A3 (en) * 2005-04-15 2007-03-29 Univ North Carolina State Methods and compositions to modulate adhesion and stress tolerance in bacteria
CN109628364A (zh) * 2019-01-03 2019-04-16 江南大学 一种提高乳酸菌对酸性条件的耐受能力的方法

Also Published As

Publication number Publication date
WO1998010102A3 (fr) 1998-05-14
FR2753202A1 (fr) 1998-03-13
CA2266190A1 (fr) 1998-03-12
AU4122897A (en) 1998-03-26
EP0941308A2 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
US10519519B2 (en) Phage insensitive streptococcus thermophilus
Poyart et al. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis
Rodtong et al. Differentiation of Lactobacillus strains by ribotyping
Wilson et al. Human colonic biota studied by ribosomal DNA sequence analysis
Simonet et al. Invasin production by Yersinia pestis is abolished by insertion of an IS200-like element within the inv gene
DK2336362T3 (en) USE OF CRISPR-ASSOCIATED GENES (CAS)
Ginocchio et al. Naturally occurring deletions in the centisome 63 pathogenicity island of environmental isolates of Salmonella spp
CA2738781C (en) Reduced colonization of microbes at the mucosa
CN108359643B (zh) 新型金黄色葡萄球菌噬菌体及其组合物和应用
JP2008523804A (ja) 非病原性の非侵襲性グラム陽性細菌中での複合多糖の異種発現および分泌による、病原性グラム陽性細菌の莢膜多糖の新規効率的製造方法
WO2008012538A2 (en) Live vaccine strains of francisella
CN110621776A (zh) 新型屎肠球菌噬菌体Ent-FAP-4及其用于抑制屎肠球菌增殖的用途
EP2195434A1 (de) Plasmidproduktion und expression rekombinanter proteine in ohne antibiotika kultivierten zellen
EP0941308A2 (de) Multiresistente bakterien, verfahren zur herstellung und verwendung
Tannock Mini review: Molecular genetics: A new tool for investigating the microbial ecology of the gastrointestinal tract?
Bergström et al. Extrachromosomal elements of spirochetes
KR20140002463A (ko) 디포신 및 그의 사용 방법
KR20160062289A (ko) 신규 암 치료용 살모넬라 균주 및 이의 용도
Ketley et al. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103
Vickerman et al. Construction of recombination-deficient strains of Streptococcus gordonii by disruption of the recA gene
KR102903717B1 (ko) 병원성 대장균의 증식을 억제하기 위한 조성물 및 방법
Yother et al. Genetics of Streptococcus pneumoniae
CN114763537B (zh) 溶藻弧菌噬菌体vB_ValS_R13Z及其应用
WO2024096123A1 (ja) 遺伝子が改変された微生物およびその生産方法
Dasen Molecular identification and applied genetics of propionibacteria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
ENP Entry into the national phase

Ref document number: 2266190

Country of ref document: CA

Ref country code: CA

Ref document number: 2266190

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997938986

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09147782

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998512313

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997938986

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997938986

Country of ref document: EP